- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Merck, Gilead report mixed outcomes in key lung cancer, HIV studies | ||
| 18:46 | Stealthy startup Treeline plans a reverse merger | ||
| 18:46 | GSK boosts cancer pipeline with $11B Nuvalent buyout | ||
| Mo | City banks nearly $100M for next-gen RNAi drugs | ||
| Mo | Roche stakes $700M on Nurix's protein-degrading drug | ||
| Mo | Tango data add to growing momentum for pancreatic cancer drugs | ||
| Mo | Incyte to buy blood disorder drug in possibly $2B deal | ||
| Mo | J&J to acquire Firefly, maker of 'degrader' antibody drugs, for up to $1B | ||
| Mo | ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option | ||
| Mo | Precision under pressure: Logistic solutions for nuclear medicine scalability | ||
| Mo | Innovation alone is no longer enough in biopharma | ||
| Fr | Study data convince Lundbeck to push new migraine drug forward | ||
| Fr | Generic drugmakers gain key victory in 'skinny label' patent case | ||
| Fr | Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? | ||
| Do | An ADC specialist sinks on safety concerns for blood cancer drug | ||
| Do | Alnylam, Inceptive ink AI deal potentially worth $2B | ||
| Do | A Spanish biotech banks $87M to make differentiated ADCs | ||
| Mi | Legend surges on early data for 'in vivo' lymphoma cell therapy | ||
| Mi | House bill aims to crack down on China biotech deals | ||
| Mi | NewLimit's $435M megaround; Lilly's busy dealmaking week | ||
| Mi | Lilly, Ascidian link up in RNA exon editing pact | ||
| 02.06. | Celcuity breast cancer drug misses 'lofty' expectations in ASCO-spotlighted trial | ||
| 02.06. | Eli Lilly issues data sharing ultimatum to 340B hospitals | ||
| 02.06. | Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug | ||
| 02.06. | AbiVax falls as safety worries cloud 'landmark' immune drug results |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.